Date: 2015-04-27
Type of information: Nomination
Compound:
Company: Amicus Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 27, 2015, Amicus Therapeutics, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has appointed David Allsop as Senior Vice President, International. He will be responsible for Amicus\' international organizational build out, and will lead international commercial and market access activities for migalastat monotherapy for Fabry disease. Mr. Allsop will serve as a member of the Amicus executive team reporting to Bradley L. Campbell, President and Chief Operating Officer. Mr. Allsop brings over 27 years of international General Management and commercial experience in the biopharmaceutical industry between Biogen Idec and Janssen-Cilag, with extensive operational and strategic leadership in the areas of neurology, autoimmune diseases, hemophilia, gastroenterology, dermatology, and renal. He has successfully launched three blockbuster therapies internationally as well as many other therapies both nationally and internationally. Mr. Allsop has both direct and indirect experience in securing market access and reimbursement in the European Union and international markets. Prior to joining Amicus, Mr. Allsop was instrumental in building Biogen\'s international commercial organization over the last 17 years. He most recently served as Senior Vice President, Europe and Canada, with full responsibility for the business and organization in those territories. While at Biogen he led the successful international launch of several products in the multiple sclerosis franchise, including Avonex®, Tysabri®, Fampyra®, Tecfidera® and Plegridy™ as well as taking responsibility for the hemophilia development organization. Prior to his tenure at Biogen, Mr. Allsop spent 10 years in roles of increasing responsibility at Janssen-Cilag, working in gastroenterology, dermatology and renal, including building and running a number of commercial units and taking responsibility for the Company\'s largest brand in the United Kingdom.
Financial terms:
Latest news:
